Should I buy or sell ASLAN Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ASLN shares. View ASLN analyst ratings or view top-rated stocks .

What is ASLAN Pharmaceuticals' stock price target for 2024?

3 Wall Street research analysts have issued 12-month price targets for ASLAN Pharmaceuticals' stock. Their ASLN share price targets range from $9.00 to $15.00. On average, they anticipate the company's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 2,113.5% from the stock's current price. View analysts price targets for ASLN or view top-rated stocks among Wall Street analysts .

How have ASLN shares performed in 2024?

ASLAN Pharmaceuticals' stock was trading at $0.5221 on January 1st, 2024. Since then, ASLN shares have decreased by 1.9% and is now trading at $0.5120. View the best growth stocks for 2024 here .

Are investors shorting ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals saw a decrease in short interest in March. As of March 31st, there was short interest totaling 116,800 shares, a decrease of 59.8% from the March 15th total of 290,500 shares. Based on an average trading volume of 979,300 shares, the short-interest ratio is currently 0.1 days. Approximately 0.7% of the company's shares are sold short. View ASLAN Pharmaceuticals' Short Interest .

When is ASLAN Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024. View our ASLN earnings forecast .

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.69. The company had revenue of $12 million for the quarter.

When did ASLAN Pharmaceuticals' stock split?

Shares of ASLAN Pharmaceuticals reverse split before market open on Monday, March 13th 2023. The 1-5 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of ASLAN Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , Arbutus Biopharma (ABUS) , Allena Pharmaceuticals (ALNA) , Actinium Pharmaceuticals (ATNM) , Inovio Pharmaceuticals (INO) , OPKO Health (OPK) , Onconova Therapeutics (ONTX) , Aldeyra Therapeutics (ALDX) , SCYNEXIS (SCYX) and VBI Vaccines (VBIV) .

When did ASLAN Pharmaceuticals IPO?

ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ASLN

ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free ASLN Stock Alerts

$0.51

-0.03 (-5.54%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.50
▼
$0.57
50-Day Range: $0.41
▼
$1.63
52-Week Range: $0.39
▼
$4.69

Volume: 26,010 shs
Average Volume: 858,218 shs
Market Capitalization: $8.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.33

Get ASLAN Pharmaceuticals alerts:

ASLAN Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,113.5% Upside
$11.33 Price Target
Short Interest: Healthy
0.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.20
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.68) to ($2.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
ASLAN Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ASLAN Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.73% of the float of ASLAN Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
ASLAN Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ASLAN Pharmaceuticals has recently decreased by 59.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ASLAN Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ASLAN Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ASLN.

1.6

News and Social Media Coverage

News Sentiment
ASLAN Pharmaceuticals has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for ASLAN Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for ASLN on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
MarketBeat Follows
18 people have added ASLAN Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ASLAN Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.69% of the stock of ASLAN Pharmaceuticals is held by insiders.
Percentage Held by Institutions
58.82% of the stock of ASLAN Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for ASLAN Pharmaceuticals are expected to grow in the coming year, from ($2.68) to ($2.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ASLAN Pharmaceuticals is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ASLAN Pharmaceuticals is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ASLAN Pharmaceuticals has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN)

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

ASLN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ASLN Stock News Headlines

April 19, 2024 | globenewswire.com

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice

April 16, 2024 | americanbankingnews.com

ASLAN Pharmaceuticals' (ASLN) Buy Rating Reaffirmed at HC Wainwright

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 14, 2024 | finanznachrichten.de

ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

April 12, 2024 | msn.com

ASLAN Falls On Q4 Figures

April 12, 2024 | markets.businessinsider.com

ASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023

April 12, 2024 | globenewswire.com

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 27, 2024 | globenewswire.com

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 18, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)

March 18, 2024 | finance.yahoo.com

ASLN Apr 2024 5.000 call

March 17, 2024 | seekingalpha.com

Week In Review: Under Pressure From U.S. Congress, WuXi AppTec Resigns From BIO

March 14, 2024 | finance.yahoo.com

Smart Home Healthcare Market to Reach USD 160.7 Billion by 2032, at 24.3% CAGR: Astute Analytica

March 14, 2024 | finance.yahoo.com

REGN May 2024 885.000 call

March 12, 2024 | msn.com

ASLAN Pharmaceuticals announces $5M registered direct offering

March 12, 2024 | globenewswire.com

ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering

March 12, 2024 | realmoney.thestreet.com

Piper 'confident' partner or buyer will see benefit of Aslan's eblasakimab

March 11, 2024 | msn.com

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12%

March 11, 2024 | msn.com

Bank Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading

March 6, 2024 | finance.yahoo.com

ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

March 4, 2024 | msn.com

Asian Equities Traded in US as ADRs Edge Higher Monday Afternoon

February 29, 2024 | msn.com

Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading

February 29, 2024 | globenewswire.com

ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat

February 28, 2024 | msn.com

Bank, Auto Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Wednesday

February 27, 2024 | msn.com

Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

February 20, 2024 | finance.yahoo.com

ASLAN Pharmaceuticals Limited (ASLN)

February 20, 2024 | morningstar.com

ASLAN Pharmaceuticals Ltd ADR

See More Headlines

Receive ASLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2023
Today: 4/19/2024
Next Earnings (Estimated): 4/26/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ASLN
CUSIP: N/A
CIK: 1722926
Web: www.aslanpharma.com
Phone: 65-6817-9598
Fax: 65-6225-2419
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.33
High Stock Price Target: $15.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +2,113.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,220,000.00
Net Margins: N/A
Pretax Margin: -375.12%
Return on Equity: -862.59%
Return on Assets: -82.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.11
Quick Ratio: 2.11

Sales & Book Value

Annual Sales: $12 million
Price / Sales: 0.70
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.60 per share
Price / Book: 0.85

Miscellaneous

Outstanding Shares: 16,350,000
Free Float: 15,583,000
Market Cap: $8.37 million
Optionable: Optionable
Beta: 1.45

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Carl Alan Jason Morton Firth EMBA (Age 51)
Ph.D., Founder, CEO & Executive Director
Mr. Kiran Kumar Asarpota (Age 45)
COO & Head of Finance
Mr. Ben Goodger (Age 61)
General Counsel
Mr. Stephen Doyle (Age 51)
Chief Business Officer
Dr. Alexandre Kaoukhov M.D. (Age 50)
Chief Medical Officer
Charlie Hsu
Investor Relations Director
Chi-Chin Wang
IR & Corporate Development Director

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ASLN Stock Analysis - Frequently Asked Questions

Should I buy or sell ASLAN Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ASLN shares.
View ASLN analyst ratings or view top-rated stocks.
What is ASLAN Pharmaceuticals' stock price target for 2024?: 3 Wall Street research analysts have issued 12-month price targets for ASLAN Pharmaceuticals' stock. Their ASLN share price targets range from $9.00 to $15.00. On average, they anticipate the company's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 2,113.5% from the stock's current price.
View analysts price targets for ASLN or view top-rated stocks among Wall Street analysts.
How have ASLN shares performed in 2024?: ASLAN Pharmaceuticals' stock was trading at $0.5221 on January 1st, 2024. Since then, ASLN shares have decreased by 1.9% and is now trading at $0.5120.
View the best growth stocks for 2024 here.
Are investors shorting ASLAN Pharmaceuticals?: ASLAN Pharmaceuticals saw a decrease in short interest in March. As of March 31st, there was short interest totaling 116,800 shares, a decrease of 59.8% from the March 15th total of 290,500 shares. Based on an average trading volume of 979,300 shares, the short-interest ratio is currently 0.1 days. Approximately 0.7% of the company's shares are sold short.
View ASLAN Pharmaceuticals' Short Interest.
When is ASLAN Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our ASLN earnings forecast.
How were ASLAN Pharmaceuticals' earnings last quarter?: ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.69. The company had revenue of $12 million for the quarter.

When did ASLAN Pharmaceuticals' stock split?: Shares of ASLAN Pharmaceuticals reverse split before market open on Monday, March 13th 2023. The 1-5 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
What other stocks do shareholders of ASLAN Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Onconova Therapeutics (ONTX), Aldeyra Therapeutics (ALDX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).
When did ASLAN Pharmaceuticals IPO?: ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.
How do I buy shares of ASLAN Pharmaceuticals?: Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASLN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

ASLAN Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN)

ASLN Stock Price History

ASLN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ASLN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™